Form 6-K YD Bio Ltd For: Aug 11

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of August 2026

 

Commission File Number: 001-42810

 

 

YD Bio Limited

 

 

12F., No. 3, Xingnan St.,

Nangang Dist.,

Taipei City 115001, Taiwan

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

 

 

Issuance of Press Release

 

On August 11, 2026, YD Bio Limited (the “Company”) issued a press release announcing the launch of two nutraceutical products in Taiwan, and its intent to explore additional opportunities for collaboration through a repeatable physician-partnership model. A copy of the press release is furnished as Exhibit 99.1 to this Report on Form 6-K (this “Report”) and is incorporated herein by reference.

 

The information contained in this Report, except for any quotes provided in the press release, is hereby incorporated by reference into the Company’s Registration Statement on Form S-8 (File No. 333-292554) to be a part thereof, to the extent not superseded by documents or reports subsequently filed or furnished. This Report, including Exhibit 99.1, shall not otherwise be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Forward Looking Statements

 

Matters discussed in this report may constitute forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are statements other than statements of historical facts. The words “believe”, “may”, “intend”, “expect”, “pending”, “will” and similar expressions identify forward-looking statements. The forward-looking statements in this report are based upon various assumptions. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations. Except as required by law, the Company disclaims any duty to update these forward-looking statements.

 

EXHIBIT INDEX

 

The following exhibits are being filed herewith:

 

Exhibit No.		Description
99.1		Press Release, dated August 11, 2026

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

August 11, 2026

 

YD BIO LIMITED
By:	/s/ Edmund Hen
Name:	Edmund Hen
Title:	Chief Financial Officer

 

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE, DATED AUGUST 11, 2026

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• YD Bio launches two nutraceutical products in Taiwan with physicians
• Litecoin Price Prediction Drowns 89% Below Its Peak While Pepeto Rockets
• Karsan Autonomous e-ATAK Begins Passenger Service at the World-Famous Efteling Theme Park